Indivior Pharmaceuticals, Inc.
Indivior develops, manufactures, and sells prescription drugs to treat opioid dependence and related disorders globally. Core products include SUBLOCADE injections, SUBOXONE Film/TABLET, and SUBUTEX Tablet for opioid use disorder. The company also offers OPVEE nasal spray for overdose reversal. Indivior is developing INDV-2000 for moderate to severe OUD and INDV-6001 with Alar Pharmaceuticals Inc.
Overview
Strengths
- Pricing power: gross margin has held between 80% and 84% over the last 5 years (latest 80.1%).
- Consistent growth: revenue has compounded at 11.9% a year over 4 years, rising every year.
- Shareholder-friendly capital allocation: the share count has shrunk by 2.9% a year over the last three years through buybacks.
- Improving fundamentals over the last year: return on assets up 17.0 points and asset turnover up 14.3%.
- Cheaper than its own history: P/E 21.6x vs. a historical average of 96.5x.
Weaknesses
- Eroding returns: ROIC has fallen to 0.0% from a multi-year average of 15.9%, a possible sign of a weakening moat.
- Unreliable cash generation: free cash flow was negative in 3 of the last 5 years.
- Our discounted cash flow target price (16.80 USD) is 54% below the current price.
- Earnings quality red flag: reported profit exceeds operating cash flow by 19.7% of total assets.
- Tight liquidity: current liabilities exceed current assets (current ratio 0.71).
- More expensive than its own history: EV/EBITDA 15.2x vs. a historical average of 7.5x.
Key Financial Data